Micro Imaging Technology (CE) (USOTC:MMTC)
Historical Stock Chart
From Apr 2019 to Apr 2024
Micro Imaging Technology Inc. (OTC:MMTC) announced that
it will be working in collaboration with Richard L. Walker DVM, Ph.D.,
professor of Clinical Diagnostic Bacteriology and director of the
California Animal Health and Food Safety (CAHFS) Laboratory located at
the University of California at Davis, in projects to further
demonstrate the efficacy of its laser-based microbe detection
technology. CAHFS is the backbone of the Western Institute for Food
Safety and Security whose mission is to conduct research that enhances
food safety and defense in all sectors of the food systems' continuum
from environment to consumer.
The first project will involve the exact identification of
specific characteristics of the E. coli bacteria at the strain level.
This program expands on MIT's earlier demonstrated successes in the
ability, within several minutes of testing, to determine subspecies of
E. coli. The objective is to rapidly determine the level of
resistivity of the bacteria to various antigens. According to Dr.
Walker, "Such a study could interest audiences in a number of fields,
including medical and food safety."
About Micro Imaging Technology:
The company has developed and patented a laser-based technology
for rapid microbe detection and identification. The system measures
scattered light intensity as individual microbes pass through a laser
beam. The intensity pattern of the scattered light is a direct
consequence of the size, shape and external and internal optical
characteristics of the microbe. MIT has demonstrated the ability to
detect and immediately identify the microbes Escherichia coli,
Listeria, Salmonella Staphylococcus aureus, Shigella and other
pathogenic bacteria. The company has verified its bacteria
identification process by an independent, internationally recognized
biological testing laboratory which designed and performed a
comparative test that measured the accuracy, speed and efficiency of
MIT's rapid microbe identification system against conventional gas
chromatographic and biological processes. The comparative tests were
in a double-blind experiment, meaning that the independent laboratory
technicians, using the MIT system and the well-recognized alternative
processes, were not aware of the various microbes' identity. The Test
Report, in the company's opinion, demonstrated superbly the accuracy,
speed and efficiency of the MIT system over conventional processes.
The Report is available from the company.
This release contains statements that are forward-looking in
nature. Statements that are predictive in nature, that depend upon or
refer to future events or conditions or that include words such as
"expects," "anticipates," "intends," "plans," "believes," "estimates,"
and similar expressions are forward-looking statements. These
statements are made based upon information available to the company as
of the date of this release, and we assume no obligation to update any
such forward-looking statements. These statements are not guarantees
of future performance and actual results could differ materially from
our current expectations. Factors that could cause or contribute to
such differences include, but are not limited to dependence on
suppliers; short product life cycles and reductions in unit selling
prices; delays in development or shipment of new products; lack of
market acceptance of our new products or services; inability to
continue to develop competitive new products and services on a timely
basis; introduction of new products or services by major competitors;
our ability to attract and retain qualified employees; inability to
expand our operations to support increased growth; and declining
economic conditions, including a recession. These and other factors
and risks associated with our business are discussed from time to time
within our filings with the Securities and Exchange Commission.